<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Drug Policy</journal-id><journal-id journal-id-type="iso-abbrev">Int. J. Drug Policy</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>The International journal on drug policy</journal-title></journal-title-group><issn pub-type="ppub">0955-3959</issn><issn pub-type="epub">1873-4758</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC5798603</article-id><article-id pub-id-type="pmcid-ver">PMC5798603.1</article-id><article-id pub-id-type="pmcaid">5798603</article-id><article-id pub-id-type="pmcaiid">5798603</article-id><article-id pub-id-type="manuscript-id">NIHMS937607</article-id><article-id pub-id-type="pmid">28578865</article-id><article-id pub-id-type="doi">10.1016/j.drugpo.2017.05.021</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS937607</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA937607</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>INITIATING HCV TREATMENT WITH DIRECT ACTING AGENTS IN OPIOID AGONIST TREATMENT: WHEN TO START FOR PEOPLE CO-INFECTED WITH HIV?</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Panagiotoglou</surname><given-names initials="D">Dimitra</given-names></name><xref ref-type="aff" rid="A1">a</xref><xref ref-type="author-notes" rid="FN1">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Krebs</surname><given-names initials="E">Emanuel</given-names></name><xref ref-type="aff" rid="A1">a</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Min</surname><given-names initials="JE">Jeong Eun</given-names></name><xref ref-type="aff" rid="A1">a</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Olding</surname><given-names initials="M">Michelle</given-names></name><xref ref-type="aff" rid="A1">a</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ahamad</surname><given-names initials="K">Keith</given-names></name><xref ref-type="aff" rid="A1">a</xref><xref ref-type="aff" rid="A3">c</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ti</surname><given-names initials="L">Lianping</given-names></name><xref ref-type="aff" rid="A1">a</xref><xref ref-type="aff" rid="A2">b</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Montaner</surname><given-names initials="JSG">Julio S.G.</given-names></name><xref ref-type="aff" rid="A1">a</xref><xref ref-type="aff" rid="A2">b</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nosyk</surname><given-names initials="B">Bohdan</given-names></name><xref ref-type="aff" rid="A1">a</xref><xref ref-type="aff" rid="A4">d</xref></contrib></contrib-group><aff id="A1">
<label>a</label>BC Centre for Excellence in HIV/AIDS, Vancouver, Canada</aff><aff id="A2">
<label>b</label>Division of AIDS, Faculty of Medicine, University of British Columbia, Vancouver, Canada</aff><aff id="A3">
<label>c</label>Department of Family Medicine, Faculty of Medicine, University of British Columbia, Vancouver, Canada</aff><aff id="A4">
<label>d</label>Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada</aff><author-notes><corresp id="FN1"><bold>Corresponding author at:</bold> Dimitri Panagiotoglou, BC Centre for Excellence in HIV/AIDS, 1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada. <email>dpanagiotoglou@cfenet.ubc.ca</email></corresp><fn fn-type="COI-statement" id="FN2"><p id="P34"><bold>Conflict of interest</bold></p><p id="P35">All authors report no potential conflict of interest. Preliminary results of the study were presented during the HepDart 2015 conference by Dr. Bohdan Nosyk.</p></fn></author-notes><pub-date pub-type="epub"><day>01</day><month>6</month><year>2017</year></pub-date><pub-date pub-type="ppub"><month>9</month><year>2017</year></pub-date><volume>47</volume><issue-id pub-id-type="pmc-issue-id">305987</issue-id><fpage>169</fpage><lpage>176</lpage><pub-history><event event-type="nihms-submitted"><date><day>30</day><month>01</month><year>2018</year></date></event><event event-type="pmc-release"><date><day>01</day><month>09</month><year>2018</year></date></event><event event-type="pmc-live"><date><day>01</day><month>09</month><year>2018</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-10-30 03:25:31.490"><day>30</day><month>10</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms937607.pdf"/><abstract><sec id="S1"><title>Background</title><p id="P1">Direct acting antivirals (DAA) raise the possibility of eliminating Hepatitis C virus (HCV) among people who inject drugs (PWID). However, concerns regarding treatment retention and reinfection challenge implementation efforts. Opioid agonist treatment (OAT) provides an opportunity to engage HCV-positive PWID into DAA-based treatment. Our objective was to identify when OAT adherence sufficiently improved to inform DAA initiation in OAT settings, assuming continuous OAT retention for at least twelve weeks is necessary to complete the DAA treatment course.</p></sec><sec id="S2"><title>Methods</title><p id="P2">This was a retrospective cohort study of HCV/HIV co-infected PWID from a population-level linked administrative database of people diagnosed and living with HIV in British Columbia, Canada between 01/1996 and 12/2013. We used monthly follow-up data after initial OAT entry and considered the effects of demographics, disease severity, and HIV and OAT treatment characteristics over time on the probability of subsequent OAT retention of &#8805;12 weeks, and &#8805;8 weeks for sensitivity analysis. We fit a generalized linear mixed model to the overall study population, and on stratified samples of those continuously engaged on combination antiretroviral therapy (&#8805;95% ART adherence). A set of monthly indicator variables (months 1, &#8230;, 7, &gt;7) were included to fulfil the study objective.</p></sec><sec id="S3"><title>Results</title><p id="P3">Our study included 1427 HCV/HIV co-infected PWID (39.0% female, 68.8% OAT-naive). The odds of subsequent twelve-week retention in OAT were statistically significantly greater in month 3 versus month 1 (adjusted odds ratio: 1.18; 95% confidence interval: 1.02, 1.37); and the odds of subsequent 8- week retention in OAT were statistically significantly greater in month 2 versus month 1 (1.15, 95% CI: 1.02, 1.31). Among continuously ART-adherent individuals, the odds of subsequent twelve-week retention were not statistically significantly greater than in month 1 (month 2: 1.12 (0.82,1.51); month 3: 1.08 (0.79, 1.47); month 4: 1.24 (0.91, 1.71)).</p></sec><sec id="S4"><title>Conclusion</title><p id="P4">We provide evidence that among HCV/HIV co-infected PWID, those retained in OAT for three or more months had higher odds of completing an additional twelve weeks of OAT, compared to no difference in those already receiving ART. These data may have implications for adherence to DAA therapy and further studies are needed to understand the optimal timing of DAA therapy in PWID receiving and not receiving OAT.</p></sec></abstract><kwd-group><kwd>Hepatitis C virus</kwd><kwd>HIV</kwd><kwd>Opioid agonist treatment</kwd><kwd>People who inject drugs</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>